PIK3CA and neoplasm: PTCs harboring BRAFV600E mutations often display concurrent mutations in PIK3CA and AKT1; mutations in the SWI/SNF complex have also been identified in in vivo models coexisting with BRAFV600E mutations, jointly promoting tumor progression [15].